Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090779 · ClinicalTrials.gov registry record · Phase 2
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
A Phase 2 study, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Terminated
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00090779: Clinical Trial Phase 2 study, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
NCT00090779 is a Phase 2 study that was terminated before completion, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 130 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00090779, a Phase 2 study, was terminated before completion, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are first infected.
Primary Outcome
The primary endpoint is (i) the average of log10 viral loads (VL) at wks 72 and 76 for participants who continued to wk 72 off ARV for the DT arm, (ii) average wk 72 and 76 VL for those who continued to wk 36 off ARV for the IT arm and (iii) an assigned VL rank for the "failures" who needed ARVs or met criteria for entry into Step 2 prior to these study visits. The assigned rank for the failures was either the last observed rank carried forward or the worst rank relative to the other possible ou
Interventions
- DRUG Lopinavir/Ritonavir
- DRUG Emtricitabine/ tenofovir disoproxil fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2005-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Why NCT00090779 stopped before completion
NCT00090779 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Lopinavir/Ritonavir is the first listed.
NCT00090779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00090779 about?
NCT00090779 is a clinical study titled "Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV". Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drug...
What is the current status of trial NCT00090779?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2005-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00090779?
The interventions under investigation include: Lopinavir/Ritonavir (DRUG), Emtricitabine/ tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT00090779?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00090779's enrollment target sits among peer trials
130 543rd of 2000 higher than 1,448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia